Marisa Wexler, MS,  senior science writer—

Premature newborns who are treated for eye problems with anti-VEGF therapies may be at increased risk of developing pulmonary hypertension, a new study suggests. “Future studies evaluating the safety of anti-VEGF therapy should include pulmonary hypertension as a key clinical outcome. This is especially important as anti-VEGF treatment usage…

The U.S. Food and Drug Administration (FDA) granted breakthrough device designation to the CorVista System, a point-of-care diagnostic tool that aims to use non-invasive tests and machine learning to help diagnose pulmonary hypertension and other cardiovascular disorders. The designation gives CorVista Health, the system’s developer, certain benefits aimed…

Switching from weekly infusions of levosimendan to a daily oral version of the experimental medication was well-tolerated among people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to new trial data. That data, from the open-label extension phase of the HELP Phase 2 clinical…

Treatment with sotatercept, given in addition to standard therapies, significantly improves exercise capacity in people with pulmonary arterial hypertension (PAH). Those are the new findings of a pivotal Phase 3 clinical trial called STELLAR, which tested the therapy’s safety and efficacy in improving PAH patients’ ability to walk. Now,…

Two weeks of aerobic exercise improved blood flow parameters and survival in a rat model of pulmonary arterial hypertension (PAH), and altered the energy usage of cells in the heart, a new study reports. “Our data support the beneficial effect of exercise training in this clinical setting, as two…

A high dose of Tyvaso (inhaled treprostinil) — at least nine breaths four times per day — is more effective at preventing clinical worsening than lower doses for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), a new study indicates. “This analysis further reinforces that [Tyvaso]…

The U.S. Food and Drug Administration (FDA) has accepted a proposal from Bellerophon Therapeutics to reduce the size of a Phase 3 clinical trial that’s testing its INOpulse device on people with pulmonary fibrosis (PF) at risk of pulmonary hypertension (PH). The change, made based on analyses from…

Treatment with Pulnovo Medical‘s pulmonary artery denervation (PADN) device improved exercise capacity, blood flow dynamics, and clinical outcomes for pulmonary arterial hypertension (PAH) patients in a clinical trial called PADN-CFDA, the company announced. “The PADN-CFDA results are very important because this was an adequately powered randomized controlled trial,…

Mice that lack a protein called AMPK in the muscle around their blood vessels develop a lethal disease that appears very similar to persistent pulmonary hypertension of the newborn (PPHN), suggesting that AMPK may be a useful therapeutic target in this disease, according to a new study. “This study…

Scores on standardized risk assessments showed a clear treatment effect with Orenitram (treprostinil) after three months in a pulmonary arterial hypertension (PAH) clinical trial, with patients showing risk score improvements being less likely to have clinical worsening later on. The results of this new analysis suggest early changes…

The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) have published a new set of guidelines for the diagnosis and management of pulmonary hypertension (PH). These guidelines simplify diagnostic criteria for PH, emphasizing the importance of early disease detection and the expedited referral of high-risk patients…

More than half of babies born preterm at a center in the Netherlands were found to have pulmonary hypertension (PH), a new study reports. Babies with PH were more likely to develop bronchopulmonary dysplasia (BPD), a breathing disorder where the lungs don’t develop correctly, and survival outcomes were poorer…